BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34732240)

  • 1. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
    Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
    Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
    Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
    Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.
    Lu Z; Chen H; Li S; Gong J; Li J; Zou J; Wu L; Yu J; Han W; Sun H; Jiao X; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32792358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.
    Deng S; Gu H; Chen Z; Liu Y; Zhang Q; Chen D; Yi S
    Carcinogenesis; 2024 May; 45(5):351-357. PubMed ID: 38310539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
    Iafolla MAJ; Yang C; Chandran V; Pintilie M; Li Q; Bedard PL; Hansen A; Lheureux S; Spreafico A; Razak AA; Hakgor S; Giesler A; Pugh TJ; Siu LL
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.
    Chowell D; Krishna C; Pierini F; Makarov V; Rizvi NA; Kuo F; Morris LGT; Riaz N; Lenz TL; Chan TA
    Nat Med; 2019 Nov; 25(11):1715-1720. PubMed ID: 31700181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
    Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
    Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC-I genotype and tumor mutational burden predict response to immunotherapy.
    Goodman AM; Castro A; Pyke RM; Okamura R; Kato S; Riviere P; Frampton G; Sokol E; Zhang X; Ball ED; Carter H; Kurzrock R
    Genome Med; 2020 May; 12(1):45. PubMed ID: 32430031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
    Naranbhai V; Viard M; Dean M; Groha S; Braun DA; Labaki C; Shukla SA; Yuki Y; Shah P; Chin K; Wind-Rotolo M; Mu XJ; Robbins PB; Gusev A; Choueiri TK; Gulley JL; Carrington M
    Lancet Oncol; 2022 Jan; 23(1):172-184. PubMed ID: 34895481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.
    Yang Y; Kim E; Kim S
    Genes Genomics; 2022 Apr; 44(4):509-515. PubMed ID: 35107815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
    Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
    Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
    Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA
    Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors.
    Merli P; Crivello P; Strocchio L; Pinto RM; Algeri M; Del Bufalo F; Pagliara D; Becilli M; Carta R; Gaspari S; Galaverna F; Quagliarella F; Boz G; Catanoso ML; Boccieri E; Troiano M; Fleischhauer K; Andreani M; Locatelli F
    Br J Haematol; 2023 Mar; 200(5):622-632. PubMed ID: 36385618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between germ-line HLA and immune-related adverse events.
    Jiang N; Yu Y; Zhang M; Tang Y; Wu D; Wang S; Fang Y; Zhang Y; Meng L; Li Y; Miao H; Ma P; Huang H; Li N
    Front Immunol; 2022; 13():952099. PubMed ID: 36177028
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.